{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:19:25Z","timestamp":1778757565319,"version":"3.51.4"},"reference-count":52,"publisher":"Harborside Press, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Adrenocortical carcinoma (ACC) is a rare cancer. The French ENDOCAN\u2013COMETE network was established in 2009 to coordinate care locally and nationally, and to promote research and education on malignant adrenal tumors. Evidence demonstrating the benefits of this organization is currently lacking.\n                    <jats:bold>Patients and Methods:<\/jats:bold>\n                    Patients diagnosed with ACC between 2010 and 2017 were identified from the French Network of Cancer Registries (FRANCIM). Patients were categorized based on referral to the ENDOCAN\u2013COMETE network as either referred at diagnosis (R-ACC) or not referred, or referred late (nR-ACC). Median overall survival (OS) and OS rates at 1, 5, and 10 years were compared between the R-ACC and nR-ACC groups after adjustment for prognostic parameters.\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 134 patients with ACC were identified from the FRANCIM registries, corresponding to an incidence of 1.4 cases per million person-years. Ten patients were excluded because of insufficient information regarding their health care pathway. The final analysis included 124 patients (mean age, 53.6 years; female-to-male ratio, 2:1). At diagnosis, 45.2% had European Network for the Study of Adrenal Tumours (ENSAT) stage I\u2013II disease, 48.4% had stage III\u2013IV disease, and 6.4% had an unknown stage; endocrine and\/or tumour-related symptoms were present in 62.9% of patients. Among the analyzed patients, 87 (70%) were R-ACC, whereas 37 (30%) were nR-ACC. In patients with localized stage I\u2013II ACC, OS rates were significantly higher in the R-ACC group than in the nR-ACC group: 1-year OS was 92% versus 85%, 5-year OS was 81% versus 55%, and 10-year OS was 75% versus 35%, respectively. This survival advantage remained significant after adjustment for prognostic factors (hazard ratio, 3.9;\n                    <jats:italic>P<\/jats:italic>\n                    =.026). In contrast, among patients with advanced ACC, OS rates were similar between the 2 groups.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Our study demonstrates an OS benefit for patients with stage I\u2013II ACC who were referred early to specialized centers within the ENDOCAN\u2013COMETE network. The combined use of the French cancer registries and dedicated national networks provides the strongest evidence to date demonstrating the impact of such a network.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2025.7137","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:31:59Z","timestamp":1778754719000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of the French ENDOCAN\u2013COMETE Network on Overall Survival in Rare Adrenocortical Carcinomas"],"prefix":"10.6004","volume":"24","author":[{"given":"Rossella","family":"Lib\u00e9","sequence":"first","affiliation":[{"name":"Service d\u2019Endocrinologie, H\u00f4pital Cochin, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Faron","sequence":"additional","affiliation":[{"name":"Service de Chirurgie Visc\u00e9rale Oncologique, Gustave Roussy Cancer Campus, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Sophie","family":"Foucan","sequence":"additional","affiliation":[{"name":"Registre du Cancer H\u00e9rault, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Castinetti","sequence":"additional","affiliation":[{"name":"Service d\u2019Endocrinologie, H\u00f4pital La Timone, CHU de Marseille, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magalie","family":"Haissaguerre","sequence":"additional","affiliation":[{"name":"Service d\u2019Endocrinologie, H\u00f4pital Haut-L\u00e9v\u00eaque, CHU de Bordeaux, Pessac, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Sophie","family":"Woronoff","sequence":"additional","affiliation":[{"name":"Registre du Cancer Doubs, Universit\u00e9 de la Franche-Comt\u00e9, Besan\u00e7on, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Drui","sequence":"additional","affiliation":[{"name":"Service d\u2019Endocrinologie, Diab\u00e9tologie et Nutrition, Institut du Thorax, Nantes Universit\u00e9, CHU de Nantes, Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karima","family":"Hammas","sequence":"additional","affiliation":[{"name":"Registre du Cancer Haut-Rhin, Mulhouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solange","family":"Grunenwald","sequence":"additional","affiliation":[{"name":"Service d\u2019Endocrinologie, H\u00f4pital Purpan, CHU de Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Tr\u00e9tarre","sequence":"additional","affiliation":[{"name":"Registre du Cancer H\u00e9rault, Institut du Cancer de Montpellier, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Delafosse","sequence":"additional","affiliation":[{"name":"Registre du Cancer Isere, Grenoble-Alpes University Hospital, Grenoble, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Laboureau","sequence":"additional","affiliation":[{"name":"Service d\u2019Endocrinologie, CHU d\u2019Angers, Angers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Molinie","sequence":"additional","affiliation":[{"name":"Registre du Cancer Loire-Atlantique et Vend\u00e9e, Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Cowppli-Bony","sequence":"additional","affiliation":[{"name":"Registre du Cancer Loire-Atlantique et Vend\u00e9e, Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Do Cao","sequence":"additional","affiliation":[{"name":"Service d\u2019Endocrinologie, CHU de Lille, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Bara","sequence":"additional","affiliation":[{"name":"Registre du Cancer Manche, CH du Cotentin, Cherbourg en Cotentin, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lap\u00f4tre-Ledoux","sequence":"additional","affiliation":[{"name":"Registre du Cancer Somme, CHU Amiens-Picardie, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Grosclaude","sequence":"additional","affiliation":[{"name":"Registre du Cancer Tarn Cancer, Claudius Regaud Institute, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine D.","family":"Plouvier","sequence":"additional","affiliation":[{"name":"Registre du Cancer Lille Area General, GCS-C2RC Alliance Cancer, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautier","family":"Defossez","sequence":"additional","affiliation":[{"name":"Registre du Cancer Poitou-Charentes, Poitiers University Hospital, Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"D\u2019Almeida","sequence":"additional","affiliation":[{"name":"Registre du Cancer Haute-Vienne, CHU de Limoges, Limoges, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene","family":"Lasolle","sequence":"additional","affiliation":[{"name":"F\u00e9d\u00e9ration d\u2019Endocrinologie, H\u00f4pital Louis Pradel, Hospices Civils de Lyon et Universit\u00e9 Lyon, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Goichot","sequence":"additional","affiliation":[{"name":"Service d\u2019Endocrinologie, CHU Strasbourg, Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Lamartina","sequence":"additional","affiliation":[{"name":"Service de Canc\u00e9rologie Endocrine, Gustave Roussy Cancer Campus, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Cristante","sequence":"additional","affiliation":[{"name":"Service d\u2019Endocrinologie CHU de Grenoble Alpes, Universit\u00e9 Grenoble Alpes, Grenoble Alpes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9gol\u00e8ne","family":"Hescot","sequence":"additional","affiliation":[{"name":"D\u00e9partement Drogues D\u00e9veloppement et Innovation (D3i), Institut Curie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Poiseuil","sequence":"additional","affiliation":[{"name":"Registre du Cancer Gironde, CHU de Bordeaux, Universit\u00e9 de Bordeaux, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Hadoux","sequence":"additional","affiliation":[{"name":"Service de Canc\u00e9rologie Endocrine, Gustave Roussy Cancer Campus, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Moog","sequence":"additional","affiliation":[{"name":"Service de Canc\u00e9rologie Endocrine, Gustave Roussy Cancer Campus, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Bertherat","sequence":"additional","affiliation":[{"name":"Service d\u2019Endocrinologie, H\u00f4pital Cochin, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Tabarin","sequence":"additional","affiliation":[{"name":"Service d\u2019Endocrinologie, H\u00f4pital Haut-L\u00e9v\u00eaque, CHU de Bordeaux, Pessac, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaelle","family":"Coureau","sequence":"additional","affiliation":[{"name":"Registre du Cancer Gironde, CHU de Bordeaux, Universit\u00e9 de Bordeaux, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[{"name":"Service de Canc\u00e9rologie Endocrine, Gustave Roussy Cancer Campus, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Ann Oncol","first-page":"1476","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht M","year":"2020","unstructured":"Fassnacht M, Assie G, Baudin E,  Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:1476\u20131490."},{"key":"B2","series-title":"Lancet Diabetes Endocrinol","first-page":"438","article-title":"Adrenocortical carcinoma: a practical guide for clinicians","volume":"13","author":"Fassnacht M","year":"2025","unstructured":"Fassnacht M, Puglisi S, Kimpel O, Terzolo M. Adrenocortical carcinoma: a practical guide for clinicians. Lancet Diabetes Endocrinol 2025;13:438\u2013452."},{"key":"B3","series-title":"Urol Clin North Am","first-page":"275","article-title":"Update on adrenocortical carcinoma","volume":"52","author":"Sarrafan-Chaharsoughi Z","year":"2025","unstructured":"Sarrafan-Chaharsoughi Z, Anari PY, Malayeri AA,  Update on adrenocortical carcinoma. Urol Clin North Am 2025;52:275\u2013286."},{"key":"B4","series-title":"Cancer","first-page":"243","article-title":"Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification","volume":"115","author":"Fassnacht M","year":"2009","unstructured":"Fassnacht M, Johanssen S, Quinkler M,  Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification.  Cancer 2009;115:243\u2013250."},{"key":"B5","series-title":"J Urol","first-page":"805","article-title":"Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database","volume":"186","author":"Kutikov A","year":"2011","unstructured":"Kutikov A, Mallin K, Canter D,  Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database. J Urol 2011;186:805\u2013810."},{"key":"B6","series-title":"Eur J Cancer","first-page":"2579","article-title":"Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993","volume":"49","author":"Kerkhofs TM","year":"2013","unstructured":"Kerkhofs TM, Verhoeven RH, Van der Zwan JM,  Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer 2013;49:2579\u20132586."},{"key":"B7","series-title":"Eur J Endocrinol","first-page":"25","article-title":"S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study","volume":"186","author":"Elhassan YS","year":"2021","unstructured":"Elhassan YS, Altieri B, Berhane S,  S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. Eur J Endocrinol 2021;186:25\u201336."},{"key":"B8","series-title":"Eur J Cancer","first-page":"713","article-title":"The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation","volume":"46","author":"Lughezzani G","year":"2010","unstructured":"Lughezzani G, Sun M, Perrotte P,  The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer 2010;46:713\u2013719."},{"key":"B9","series-title":"Ann Oncol","first-page":"2119","article-title":"Prognostic factors in stage. adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"Libe R","year":"2015","unstructured":"Libe R, Borget I, Ronchi CL,  Prognostic factors in stage. adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol 2015;26:2119\u20132125."},{"key":"B10","series-title":"Best Pract Res Clin Endocrinol Metab","first-page":"101408","article-title":"Surgery for adrenocortical carcinoma: when and how?","volume":"34","author":"Sinclair T","year":"2020","unstructured":"Sinclair T, Gillis A, Alobuia WM,  Surgery for adrenocortical carcinoma: when and how? Best Pract Res Clin Endocrinol Metab 2020;34:101408."},{"key":"B11","article-title":"Les Plans cancer (2003-2019): le pilotage national de la lutte contre les cancers","unstructured":"Institut National du Cancer. Les Plans cancer (2003-2019): le pilotage national de la lutte contre les cancers. Accessed March 11, 2026. Available at: https:\/\/www.e-cancer.fr\/Institut-national-du-cancer\/Strategie-de-lutte-contre-les-cancers-en-France\/Les-Plans-cancer\/Le-Plan-cancer-2009-2013"},{"key":"B12","series-title":"Am J Surg Pathol","first-page":"1194","article-title":"Adrenocortical tumors: improving the practice of the Weiss system through virtual microscopy: a National Program of the French Network INCa-COMETE","volume":"36","author":"Tissier F","year":"2012","unstructured":"Tissier F, Aubert S, Leteurtre E,  Adrenocortical tumors: improving the practice of the Weiss system through virtual microscopy: a National Program of the French Network INCa-COMETE. Am J Surg Pathol 2012;36:1194\u20131201."},{"key":"B13","article-title":"Thesaurus Corticosurr\u00e9nalome (r\u00e9commandation)","unstructured":"R\u00e9seau COMETE Cancers de la surr\u00e9nale, Programme Cancers Rares INCa. Thesaurus Corticosurr\u00e9nalome (r\u00e9commandation). Accessed March 11, 2026. Available at: https:\/\/www.sfendocrino.org\/_images\/mediatheque\/articles\/pdf\/INCA%20Comete\/2014%20thesaurus_corticosurrenalome_2014.pdf"},{"key":"B14","series-title":"Bull Cancer","first-page":"707","article-title":"Guidelines of the French National ENDOCAN\u2013COMETE, Association of Endocrine Surgery, Society of Urology for the management of adrenocortical carcinoma","volume":"110","author":"Libe R","year":"2023","unstructured":"Libe R, Haissaguerre M, Renaudin K,  Guidelines of the French National ENDOCAN\u2013COMETE, Association of Endocrine Surgery, Society of Urology for the management of adrenocortical carcinoma. Bull Cancer 2023;110:707\u2013730."},{"key":"B15","series-title":"N Engl J Med","first-page":"2189","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht M","year":"2012","unstructured":"Fassnacht M, Terzolo M, Allolio B,  Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012;366:2189\u20132197."},{"key":"B16","series-title":"J Clin Endocrinol Metab","first-page":"841","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"Beuschlein F","year":"2015","unstructured":"Beuschlein F, Weigel J, Saeger W,  Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab 2015;100:841\u2013849."},{"key":"B17","series-title":"Nat Genet","first-page":"607","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assie G","year":"2014","unstructured":"Assie G, Letouze E, Fassnacht M,  Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 2014;46:607\u2013612."},{"key":"B18","series-title":"Eur J Cancer","first-page":"112917","article-title":"Outcome of adrenocortical carcinoma patients included in early phase clinical trials: results from the French network ENDOCAN\u2013COMETE","volume":"189","author":"Hescot S","year":"2023","unstructured":"Hescot S, Debien V, Hadoux J,  Outcome of adrenocortical carcinoma patients included in early phase clinical trials: results from the French network ENDOCAN\u2013COMETE. Eur J Cancer 2023;189:112917."},{"key":"B19","series-title":"Lancet Diabetes Endocrinol","first-page":"720","article-title":"Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicenter, open-label, randomised, phase 3 trial and observational study","volume":"11","author":"Terzolo M","year":"2023","unstructured":"Terzolo M, Fassnacht M, Perotti P,  Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicenter, open-label, randomised, phase 3 trial and observational study. Lancet Diabetes Endocrinol 2023;11:720\u2013730."},{"key":"B20","series-title":"Eur J Endocrinol","first-page":"G1","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"189","author":"Fassnacht M","year":"2023","unstructured":"Fassnacht M, Tsagarakis S, Terzolo M,  European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2023;189:G1\u201342."},{"key":"B21","series-title":"J Clin Endocrinol Metab","first-page":"4925","article-title":"Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers","volume":"95","author":"Fassnacht M","year":"2010","unstructured":"Fassnacht M, Johanssen S, Fenske W,  Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 2010;95:4925\u20134932."},{"key":"B22","series-title":"Ann Oncol","first-page":"1407","article-title":"Surgery in reference centers improves survival of sarcoma patients: a nationwide study","volume":"30","author":"Blay JY","year":"2019","unstructured":"Blay JY, Honore C, Stoeckle E,  Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann Oncol 2019;30:1407."},{"key":"B23","series-title":"Ann Oncol","first-page":"351","article-title":"Improved nationwide survival of sarcoma patients with a network of reference centers","volume":"35","author":"Blay JY","year":"2024","unstructured":"Blay JY, Penel N, Valentin T,  Improved nationwide survival of sarcoma patients with a network of reference centers. Ann Oncol 2024;35:351\u2013363."},{"key":"B24","series-title":"Eur Urol","first-page":"832","article-title":"Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer","volume":"65","author":"Berruti A","year":"2014","unstructured":"Berruti A, Fassnacht M, Haak H,  Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol 2014;65:832\u2013838."},{"key":"B25","series-title":"Eur J Endocrinol","first-page":"G1","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht M","year":"2018","unstructured":"Fassnacht M, Dekkers OM, Else T,  European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2018;179:G1\u201346."},{"key":"B26","series-title":"Pediatr Blood Cancer","first-page":"e27384","article-title":"Impact of the Interdiscipli nary Tumor Board of the Cooperative Ewing Sarcoma Study Group on local therapy and overall survival of Ewing sarcoma patients after induction therapy","volume":"65","author":"Kreyer J","year":"2018","unstructured":"Kreyer J, Ranft A, Timmermann B,  Impact of the Interdiscipli nary Tumor Board of the Cooperative Ewing Sarcoma Study Group on local therapy and overall survival of Ewing sarcoma patients after induction therapy. Pediatr Blood Cancer 2018;65:e27384."},{"key":"B1","series-title":"Ann Oncol","first-page":"1476","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht M","year":"2020","unstructured":"Fassnacht M, Assie G, Baudin E,  Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:1476\u20131490."},{"key":"B2","series-title":"Lancet Diabetes Endocrinol","first-page":"438","article-title":"Adrenocortical carcinoma: a practical guide for clinicians","volume":"13","author":"Fassnacht M","year":"2025","unstructured":"Fassnacht M, Puglisi S, Kimpel O, Terzolo M. Adrenocortical carcinoma: a practical guide for clinicians. Lancet Diabetes Endocrinol 2025;13:438\u2013452."},{"key":"B3","series-title":"Urol Clin North Am","first-page":"275","article-title":"Update on adrenocortical carcinoma","volume":"52","author":"Sarrafan-Chaharsoughi Z","year":"2025","unstructured":"Sarrafan-Chaharsoughi Z, Anari PY, Malayeri AA,  Update on adrenocortical carcinoma. Urol Clin North Am 2025;52:275\u2013286."},{"key":"B4","series-title":"Cancer","first-page":"243","article-title":"Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification","volume":"115","author":"Fassnacht M","year":"2009","unstructured":"Fassnacht M, Johanssen S, Quinkler M,  Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification.  Cancer 2009;115:243\u2013250."},{"key":"B5","series-title":"J Urol","first-page":"805","article-title":"Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database","volume":"186","author":"Kutikov A","year":"2011","unstructured":"Kutikov A, Mallin K, Canter D,  Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database. J Urol 2011;186:805\u2013810."},{"key":"B6","series-title":"Eur J Cancer","first-page":"2579","article-title":"Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993","volume":"49","author":"Kerkhofs TM","year":"2013","unstructured":"Kerkhofs TM, Verhoeven RH, Van der Zwan JM,  Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer 2013;49:2579\u20132586."},{"key":"B7","series-title":"Eur J Endocrinol","first-page":"25","article-title":"S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study","volume":"186","author":"Elhassan YS","year":"2021","unstructured":"Elhassan YS, Altieri B, Berhane S,  S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. Eur J Endocrinol 2021;186:25\u201336."},{"key":"B8","series-title":"Eur J Cancer","first-page":"713","article-title":"The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation","volume":"46","author":"Lughezzani G","year":"2010","unstructured":"Lughezzani G, Sun M, Perrotte P,  The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer 2010;46:713\u2013719."},{"key":"B9","series-title":"Ann Oncol","first-page":"2119","article-title":"Prognostic factors in stage. adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"Libe R","year":"2015","unstructured":"Libe R, Borget I, Ronchi CL,  Prognostic factors in stage. adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol 2015;26:2119\u20132125."},{"key":"B10","series-title":"Best Pract Res Clin Endocrinol Metab","first-page":"101408","article-title":"Surgery for adrenocortical carcinoma: when and how?","volume":"34","author":"Sinclair T","year":"2020","unstructured":"Sinclair T, Gillis A, Alobuia WM,  Surgery for adrenocortical carcinoma: when and how? Best Pract Res Clin Endocrinol Metab 2020;34:101408."},{"key":"B11","article-title":"Les Plans cancer (2003-2019): le pilotage national de la lutte contre les cancers","unstructured":"Institut National du Cancer. Les Plans cancer (2003-2019): le pilotage national de la lutte contre les cancers. Accessed March 11, 2026. Available at: https:\/\/www.e-cancer.fr\/Institut-national-du-cancer\/Strategie-de-lutte-contre-les-cancers-en-France\/Les-Plans-cancer\/Le-Plan-cancer-2009-2013"},{"key":"B12","series-title":"Am J Surg Pathol","first-page":"1194","article-title":"Adrenocortical tumors: improving the practice of the Weiss system through virtual microscopy: a National Program of the French Network INCa-COMETE","volume":"36","author":"Tissier F","year":"2012","unstructured":"Tissier F, Aubert S, Leteurtre E,  Adrenocortical tumors: improving the practice of the Weiss system through virtual microscopy: a National Program of the French Network INCa-COMETE. Am J Surg Pathol 2012;36:1194\u20131201."},{"key":"B13","article-title":"Thesaurus Corticosurr\u00e9nalome (r\u00e9commandation)","unstructured":"R\u00e9seau COMETE Cancers de la surr\u00e9nale, Programme Cancers Rares INCa. Thesaurus Corticosurr\u00e9nalome (r\u00e9commandation). Accessed March 11, 2026. Available at: https:\/\/www.sfendocrino.org\/_images\/mediatheque\/articles\/pdf\/INCA%20Comete\/2014%20thesaurus_corticosurrenalome_2014.pdf"},{"key":"B14","series-title":"Bull Cancer","first-page":"707","article-title":"Guidelines of the French National ENDOCAN\u2013COMETE, Association of Endocrine Surgery, Society of Urology for the management of adrenocortical carcinoma","volume":"110","author":"Libe R","year":"2023","unstructured":"Libe R, Haissaguerre M, Renaudin K,  Guidelines of the French National ENDOCAN\u2013COMETE, Association of Endocrine Surgery, Society of Urology for the management of adrenocortical carcinoma. Bull Cancer 2023;110:707\u2013730."},{"key":"B15","series-title":"N Engl J Med","first-page":"2189","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht M","year":"2012","unstructured":"Fassnacht M, Terzolo M, Allolio B,  Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012;366:2189\u20132197."},{"key":"B16","series-title":"J Clin Endocrinol Metab","first-page":"841","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"Beuschlein F","year":"2015","unstructured":"Beuschlein F, Weigel J, Saeger W,  Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab 2015;100:841\u2013849."},{"key":"B17","series-title":"Nat Genet","first-page":"607","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assie G","year":"2014","unstructured":"Assie G, Letouze E, Fassnacht M,  Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 2014;46:607\u2013612."},{"key":"B18","series-title":"Eur J Cancer","first-page":"112917","article-title":"Outcome of adrenocortical carcinoma patients included in early phase clinical trials: results from the French network ENDOCAN\u2013COMETE","volume":"189","author":"Hescot S","year":"2023","unstructured":"Hescot S, Debien V, Hadoux J,  Outcome of adrenocortical carcinoma patients included in early phase clinical trials: results from the French network ENDOCAN\u2013COMETE. Eur J Cancer 2023;189:112917."},{"key":"B19","series-title":"Lancet Diabetes Endocrinol","first-page":"720","article-title":"Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicenter, open-label, randomised, phase 3 trial and observational study","volume":"11","author":"Terzolo M","year":"2023","unstructured":"Terzolo M, Fassnacht M, Perotti P,  Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicenter, open-label, randomised, phase 3 trial and observational study. Lancet Diabetes Endocrinol 2023;11:720\u2013730."},{"key":"B20","series-title":"Eur J Endocrinol","first-page":"G1","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"189","author":"Fassnacht M","year":"2023","unstructured":"Fassnacht M, Tsagarakis S, Terzolo M,  European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2023;189:G1\u201342."},{"key":"B21","series-title":"J Clin Endocrinol Metab","first-page":"4925","article-title":"Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers","volume":"95","author":"Fassnacht M","year":"2010","unstructured":"Fassnacht M, Johanssen S, Fenske W,  Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 2010;95:4925\u20134932."},{"key":"B22","series-title":"Ann Oncol","first-page":"1407","article-title":"Surgery in reference centers improves survival of sarcoma patients: a nationwide study","volume":"30","author":"Blay JY","year":"2019","unstructured":"Blay JY, Honore C, Stoeckle E,  Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann Oncol 2019;30:1407."},{"key":"B23","series-title":"Ann Oncol","first-page":"351","article-title":"Improved nationwide survival of sarcoma patients with a network of reference centers","volume":"35","author":"Blay JY","year":"2024","unstructured":"Blay JY, Penel N, Valentin T,  Improved nationwide survival of sarcoma patients with a network of reference centers. Ann Oncol 2024;35:351\u2013363."},{"key":"B24","series-title":"Eur Urol","first-page":"832","article-title":"Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer","volume":"65","author":"Berruti A","year":"2014","unstructured":"Berruti A, Fassnacht M, Haak H,  Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol 2014;65:832\u2013838."},{"key":"B25","series-title":"Eur J Endocrinol","first-page":"G1","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht M","year":"2018","unstructured":"Fassnacht M, Dekkers OM, Else T,  European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2018;179:G1\u201346."},{"key":"B26","series-title":"Pediatr Blood Cancer","first-page":"e27384","article-title":"Impact of the Interdiscipli nary Tumor Board of the Cooperative Ewing Sarcoma Study Group on local therapy and overall survival of Ewing sarcoma patients after induction therapy","volume":"65","author":"Kreyer J","year":"2018","unstructured":"Kreyer J, Ranft A, Timmermann B,  Impact of the Interdiscipli nary Tumor Board of the Cooperative Ewing Sarcoma Study Group on local therapy and overall survival of Ewing sarcoma patients after induction therapy. Pediatr Blood Cancer 2018;65:e27384."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/5\/article-e257137.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/5\/article-e257137.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/5\/article-e257137.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:32:00Z","timestamp":1778754720000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/5\/article-e257137.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":52,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7137","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}